Hikma signs exclusive licensing, distribution and supply agreement with Basilea for Cresemba
![](/46/pdcnewsitem/04/23/42/hikma.jpg)
Cresemba (isavuconazole) is an injectable and oral anti-fungal product.
Hikma Pharmaceuticals has extended its current exclusive licensing, supply and distribution agreement with biopharmaceutical company, Basilea Pharmaceutica International, for its anti-infective product Zevtera (ceftobiprole), to also include Basilea’s injectable and oral anti-fungal product Cresemba (isavuconazole).
Under the terms of the amended agreement, Hikma will have the exclusive rights to register, distribute and market Cresemba in all its MENA markets leveraging Hikma’s strong local presence, sales and marketing capabilities and regulatory expertise.
Cresemba has received approvals across Europe and the US. In March 2015, the product was approved by the FDA for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis. The European marketing authorisation was granted in October 2015 to isavuconazole for the treatment of adult patients with invasive aspergillosis and for the treatment of adult patients with mucormycosis for whom amphotericin B is inappropriate.
Mazen Darwazah, Vice Chairman and CEO of MENA and Emerging Markets said: “We are delighted to be building on our partnership with Basilea enabling us to continue enhancing our growing portfolio of high value products in the MENA and reinforcing our commitment to increasing patients’ access to high-quality medicines.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance